References
- Brodde OE . β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol. Ther.117 , 1–29 (2008).
- Eschenhagen T . Beta-adrenergic signaling in heart failure adapt or die. Nat. Med.14 , 485–487 (2008).
- Eschenhagen T . Is ryanodine receptor phosphorylation key to the fight or flight response and heart failure? J. Clin. Invest.120 , 4197–4203 (2010).
- Joglar JA , AcustaAP, ShustermanNH et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US carvedilol heart failure trials program. Am. Heart J. 142 , 498–501 (2001).
- Kawada T , IshibashiT, NakazawaM, SatohS, ImaiS. Adrenoceptor-blocking activity and cardiohemodynamic effects of carvedilol in animals. J. Cardiovasc. Pharmacol.16 , 147–153 (1990).
- Kindermann M , MaackC, SchallerS et al. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 109 , 3182–3190 (2004).
- Konishi M , HaraguchiG, KimuraS et al. Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure. Circ. J. 74 , 1127–1134 (2010).
- Lechat P , HulotJS, EscolanoS et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103 , 1428–1433 (2001).
- Liggett SB , Mialet-PerezJ, Thaneemit-ChenS et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc. Natl Acad. Sci. USA 103 , 11288–11293 (2006).
- Lohse MJ , EngelhardtS, EschenhagenT. What is the role of beta-adrenergic signaling in heart failure? Circ. Res.93 , 896–906 (2003).
- Marx SO , ReikenS, HisamatsuY et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101 , 365–376 (2000).
- Mason DA , MooreJD, GreenSA, LiggettSB. A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J. Biol. Chem.274 , 12670–12674 (1999).
- Molenaar P , ChristT, RavensU, KaumannA. Carvedilol blocks β2- more than β1-adrenoceptors in human heart. Cardiovasc. Res.69 , 128–139 (2006).
- Parvez B , ChopraN Rowan S et al. A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J. Am. Coll. Cardiol.59 , 49–56 (2012).
- Petersen M , AndersenJT, HjelvangBR et al. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br. J. Clin. Pharmacol. 71 , 556–565 (2011).
- Rau T , DungenHD, EdelmannF et al. Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin. Pharmacol. Ther. 92 , 21–28 (2012).
- Takei M , FurukawaY, NaritaM et al. Sympathetic nerve stimulation activates both β1- and β2-adrenoceptors of SA and AV nodes in anesthetized dog hearts. Jpn J. Pharmacol. 59 , 23–30 (1992).
- Taylor MR . Pharmacogenetics of the human β-adrenergic receptors. Pharmacogenomics J.7 , 29–37 (2007).
- van Veldhuisen DJ , AassH, El Allaf D et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur. J. Heart Fail.8 , 539–546 (2006).
- Wisler JW , DeWireSM, WhalenEJ et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl Acad. Sci. USA 104 , 16657–16662 (2007).
- Workman AJ . Cardiac adrenergic control and atrial fibrillation. Naunyn Schmiedebergs Arch. Pharmacol.381 , 235–249 (2010).